CXCR2 and prostate carcinoma: Navarixin, one of the potent and selective antagonists of the human CXCR1/CXCR2, is also evaluated in combination with Pembrolizumab in NSCLC participants, castration‐resistant prostate cancer, or microsatellite stable colorectal cancer (NCT03473925).